Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Oric Pharmaceuticals ( (ORIC) ) is now available.
On May 23, 2025, ORIC Pharmaceuticals entered into a securities purchase agreement for a private placement of approximately 19.2 million shares of its common stock, raising around $125 million. This financing, led by SR One and involving several institutional investors, is intended to fund the company’s research and development efforts, including its clinical-stage product candidates, and is expected to support operations into the second half of 2027. The private placement, set to close on May 29, 2025, will also enable ORIC to pursue its first ORIC-944 Phase 3 trial in prostate cancer, enhancing its market positioning in oncology.
The most recent analyst rating on (ORIC) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Oric Pharmaceuticals stock, see the ORIC Stock Forecast page.
Spark’s Take on ORIC Stock
According to Spark, TipRanks’ AI Analyst, ORIC is a Neutral.
Oric Pharmaceuticals’ overall score reflects the significant risks associated with its current financial performance, characterized by ongoing losses and no revenue generation. Despite a strong balance sheet with substantial cash reserves, the company’s stock is under pressure due to bearish technical indicators and uncertain valuation metrics. The expansion of the equity incentive plan is a strategic positive but does not offset the immediate financial challenges.
To see Spark’s full report on ORIC stock, click here.
More about Oric Pharmaceuticals
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing treatments to overcome resistance in cancer. The company’s clinical stage product candidates include ORIC-944, an allosteric inhibitor for prostate cancer, and ORIC-114, a brain penetrant inhibitor targeting specific genetic mutations across multiple cancers. ORIC is also developing precision medicines targeting other cancer resistance mechanisms and operates out of South San Francisco and San Diego, California.
Average Trading Volume: 743,542
Technical Sentiment Signal: Sell
Current Market Cap: $410.9M
See more data about ORIC stock on TipRanks’ Stock Analysis page.